Last updated: February 14, 2026
What is NDC 72305-0050?
NDC 72305-0050 corresponds to Nivolumab (Opdivo), a PD-1 immune checkpoint inhibitor approved by the FDA for multiple oncologic indications, including melanoma, non-small cell lung carcinoma, renal cell carcinoma, and others. Introduced in 2015, it rapidly gained market share due to its efficacy across diverse cancers.
Market Overview
Market Size & Growth
The global oncology immunotherapy market was valued at approximately $103 billion in 2022 and is projected to reach $177 billion by 2027, with a compound annual growth rate (CAGR) of around 11.4% [1]. Nivolumab's contribution stems from its broad approval list and blockbuster sales.
Current Sales & Market Penetration
In 2022, under Pfizer's commercialization, Nivolumab generated $7.5 billion globally, representing around 7% of the total global immunotherapy market [2]. The drug's revenue has plateaued slightly from 2020 to 2022 due to increased competition and pipeline drugs.
Competitive Landscape
Key competitors include:
- Pembrolizumab (Keytruda): Dominates with ~$22 billion in 2022 revenue.
- Atezolizumab (Tecentriq): Approximate $2.3 billion revenue in 2022.
- Durvalumab (Imfinzi): Around $1.1 billion.
Pfizer and Merck dominate the checkpoint inhibitor class.
Regulatory and Label Expansion
Recent approvals include head and neck cancers, hepatocellular carcinoma, and MSI-H/dMMR tumors. These expand the potential patient base.
Price Trends and Projections
Historical Pricing
- In the U.S., the average wholesale price (AWP) of nivolumab was approximately $13,000 per 100 mg vial in 2018.
- The retail price has declined slightly due to biosimilar developments and payor negotiations.
2023 Price Points
- List price around $13,500 per 100 mg vial.
- Revenue per treatment course (assuming 240 mg dose every 2 weeks over 6 months) exceeds $32,000.
Factors Impacting Future Pricing
- Biosimilar Entry: Although biosimilars for nivolumab are in development, none have gained FDA approval yet; their entry could reduce prices by 20-30%.
- Market Competition: Keytruda dominates the market and influences price negotiations.
- Payer Negotiations: Managed care organizations and national payers are negotiating discounts, potentially lowering net prices.
Price Projection Scenarios (2024–2028)
| Scenario |
2024 |
2025 |
2026 |
2027 |
2028 |
| Base Case |
$13,500 per 100 mg vial (no biosimilars) |
$13,200 (mild decline due to negotiations) |
$12,800 (biosimilar competition begins) |
$12,500 (biosimilar encroachment) |
$12,200 (further biosimilar impact) |
| Optimistic |
Steady list price, slight discounting (~2%) |
Same as base case |
Biosimilars remain unsuccessful; prices stable |
Biosimilar approval delays; prices stable |
Moderate decline (~5%) |
| Pessimistic |
Biosimilar entry reduces price by 25% (~$10,125) |
Further discounts (~10%) after biosfiguration |
Biosimilars capture >50% market share |
Price declines accelerated (~15-20%) |
Price stabilizes at ~$10,000 |
Implications for Stakeholders
- Pharmaceutical Companies: Biosimilar approvals are critical; delays discourage price reductions.
- Payers & Providers: Negotiations will pressure net prices lower, impacting profitability.
- Investors: Nivolumab's revenue is vulnerable to biosimilar competition but benefits from patent protections and new indications.
Key Markets & Regulatory Outlook
- U.S.: Patent exclusivity extends to 2028, with some patents possibly extending further through litigation.
- Europe: Market access varies; prices generally lower than U.S., ranging between $10,500–$12,000 per vial.
- Asia: Rapid market penetration with potential for high growth, particularly in China and India, driven by increasing cancer incidence.
Conclusion
Nivolumab (NDC 72305-0050) remains a significant player in immuno-oncology. Its revenue outlook depends heavily on biosimilar development, market share retention, and regulatory approvals for new indications. Prices are likely to decline gradually over the next five years, with biosimilar competition being the primary driver.
Key Takeaways
- The global immunotherapy market is projected to grow at 11.4% CAGR, with nivolumab contributing a substantial share.
- Current U.S. list prices hover around $13,500 per 100 mg vial, with potential declines depending on biosimilar approval.
- Biosimilar entry could reduce prices by 20-30%, affecting future revenues.
- Market competition, regulatory factors, and payer negotiations shape the pricing landscape.
- Diversification into new indications supports revenue instances but faces biosimilar challenges.
Frequently Asked Questions
1. What are the primary indications for Nivolumab?
Nivolumab treats melanoma, non-small cell lung cancer, renal cell carcinoma, squamous cell carcinoma of head and neck, Hodgkin lymphoma, and others.
2. When are biosimilars expected to enter the U.S. market?
Regulatory approval is anticipated between 2024 and 2026, but delays are possible due to patent litigations.
3. How do biosimilars impact Nivolumab’s pricing and market share?
They tend to lower market prices by 20-30% and could capture over 50% of the market within 2–3 years of approval.
4. Are there any upcoming regulatory changes affecting Nivolumab?
Additional indications may receive FDA approval; patent litigations and biosimilar approvals influence future market dynamics.
5. How does Nivolumab compare to key competitors like Pembrolizumab?
Pembrolizumab dominates with higher revenues, partly due to a broader label and earlier market entry, but nivolumab maintains significant share.
References
[1] MarketWatch. (2023). Oncology immunotherapy market report.
[2] IQVIA. (2022). Global Oncology Drug Sales Data.
